Feature Athersys poised to launch pivotal stroke study next summer By Len Zehr After receiving a Special Protocol Assessment (SPA) from the FDA at the end of September, Athersys (NASDAQ:ATHX) hopes to launch a pivotal trial next summer administering its intravenous MultiStem cell... December 13, 2016